Description

10x Genomics, Inc.: What Are Their Recent Single-Cell & Spatial Technology Advancements?

10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the company experienced a 1% year-over-year decline in revenue. This outcome was primarily attributed to disruptions stemming from a sales restructuring initiative and cautious customer spending amid a challenging macroeconomic environment. As a consequence, the company has revised its full-year revenue projection to between $595 million and $605 million, indicating a 3% decrease from the previous year.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!